Amsterdam UMC, Dept. of Medical Oncology, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
UMC Utrecht Cancer Center/RAKU, Dept. of Medical Oncology, Utrecht University, Utrecht, the Netherlands.
Crit Rev Oncol Hematol. 2020 Jul;151:102975. doi: 10.1016/j.critrevonc.2020.102975. Epub 2020 Apr 27.
Patients with biliary tract cancer (BTC) have a high recurrence rate after complete surgical resection. To reduce the risk of recurrence and to improve survival, several chemotherapeutic agents that have shown to be active in locally advanced and metastatic BTC have been investigated in the adjuvant setting in prospective clinical trials. Based on the results of the BILCAP phase III trial, capecitabine was adapted as the standard of care by the ASCO clinical practice guideline. Ongoing randomized controlled trials mainly compare capecitabine with gemcitabine-based chemotherapy or chemoradiotherapy. This review provides an update of adjuvant therapy in BTC based on published data of phase II and III trials and ongoing randomized controlled trials (RCTs).
胆道癌（BTC）患者在完全手术切除后复发率很高。为了降低复发风险并提高生存率，一些在局部晚期和转移性 BTC 中表现出活性的化疗药物已在前瞻性临床试验的辅助治疗环境中进行了研究。基于 BILCAP 三期试验的结果，卡培他滨被 ASCO 临床实践指南作为标准治疗方法。正在进行的随机对照试验主要比较卡培他滨与基于吉西他滨的化疗或放化疗。本综述根据 II 期和 III 期试验及正在进行的随机对照试验（RCT）的已发表数据，提供了 BTC 辅助治疗的最新信息。
